152 related articles for article (PubMed ID: 38323173)
1. Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial.
Yu LT; Wang Z; Han YL; Zhou F; Wagner LM; Zhang SG; Li ZL; Gao YJ
Transl Pediatr; 2024 Jan; 13(1):110-118. PubMed ID: 38323173
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
3. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
5. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhang Z; Yang Y; Lu P; Li X; Chang J; Zheng R; Zhou L; Chen S; Chen X; Ren B; Gu W; Jiang X; Peng J; Huang M; Feng G; Shen P; Zhang Q; Zhang B; Huang Y; He J; Chen Y; Cao J; Wang H; Li W; Wan H; Nan K; Liao Z; Zhang C; Lin Z; Zhong D; Xu Q; Liu H; Sun T; Deng Y; Zhang L
Ann Transl Med; 2020 Mar; 8(5):234. PubMed ID: 32309381
[TBL] [Abstract][Full Text] [Related]
6. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
7. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
9. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
[TBL] [Abstract][Full Text] [Related]
10. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.
Langford P; Chrisp P
Core Evid; 2010 Oct; 5():77-90. PubMed ID: 21042544
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.
Celio L; Ricchini F; De Braud F
Patient Prefer Adherence; 2013; 7():391-400. PubMed ID: 23687442
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
16. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Hata A; Shiraishi Y; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
Oncol Ther; 2022 Jun; 10(1):253-262. PubMed ID: 35246827
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
Yang LQ; Sun XC; Qin SK; Cheng Y; Shi JH; Chen ZD; Wang QM; Zhang HL; Hu B; Liu B; Zhang QY; Wu Q; Wang D; Shu YQ; Dong J; Han BH; Wang KM; Dang CX; Li JL; Wang HB; Li BL; Lu JG; Zhang ZH; Chen YX
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28393417
[TBL] [Abstract][Full Text] [Related]
19. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
